

Outcomes Report 2018: Accountability Measures and Quality Improvements

The FH Deland Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited cancer program through the Commission on Cancer of the American College of Surgeons, we have the opportunity to participate in the quality reporting systems called Cancer Program Practice Profile Report (CP3R) and Rapid Quality Reporting System (RQRS). These quality measures are standards of care based on evidence-based clinical trials.

ACCOUNTABILITY MEASURE: 2016 BREAST

Radiation is administered within 1 year of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Expected performance >90%)

FH DELAND	91.7
State of Florida	84.7
Similar COC Approved Program	89.1
All COC Approved Programs	91.4

ACCOUNTABILITY MEASURE: 2016 BREAST

Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 years of diagnosis for women with AJCC T1c or Stage IB-III hormone receptor positive breast cancer (Expected performance >90%)

FH DELAND	93.1
State of Florida	85
Similar COC Approved Program	90.1
All COC Approved Programs	92.2

ACCOUNTABILITY MEASURE: 2016 BREAST

Combination chemotherapy is recommended or administered within 45 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 or stage 1B-3 hormone receptor negative breast cancer (Expected performance >90%)

FH DELAND	100
State of Florida	88.5
Similar COC Approved Program	91.9
All COC Approved Programs	93

QUALITY IMPROVEMENT MEASURE: 2016 BREAST

Image-or palpation-guided needle biopsy to the primary site is performed to establish diagnosis

FH DELAND	92.7
State of Florida	85.8
Similar COC Approved Program	90.9
All COC Approved Programs	91.3

SURVEILLANCE MEASURE: 2016 BREAST

Breast Conservation Surgery Rate for women with AJCC clinical stage 0, I or II breast cancer

FH DELAND	71.9
State of Florida	62.7
Similar COC Approved Program	67.4
All COC Approved Programs	62.5

ACCOUNTABILITY MEASURE: 2016 COLON

Adjuvant chemotherapy is recommended or administered within 4 months of diagnosis for patients under age 80 with stage III (lymph node positive) colon cancer
(Expected performance >90%)

FH DELAND	100
State of Florida	81.2
Similar COC Approved Program	86.7
All COC Approved Programs	88.6

QUALITY IMPROVEMENT MEASURE: 2016 COLON

Fewer than 12 nodes pathologically examined (Expected performance >85%)

FH DELAND	100
State of Florida	91
Similar COC Approved Program	90.3
All COC Approved Programs	92.8

QUALITY IMPROVEMENT MEASURE: 2016 LUNG

Surgery is not the first course of treatment for cN2 M0 lung cases (Expected performance >85%)




FH DELAND	100
State of Florida	87.6
Similar COC Approved Program	94.4
All COC Approved Programs	92.9

The Rapid Quality Reporting System (RQRS) is a quality reporting tool that outlines our current measures of standards within 3 months of diagnosis. Here are some examples of our quality measures. Expected performance is >90%, unless otherwise noted.


BREAST CANCER MEASURES




BREAST CANCER MEASURES



COLON CANCER MEASURES



Expected Performance >85%



2017 Cancer Statistics FH DeLand

Top Cancer Sites

PRIMARY SITE				GENDER		AJCC STAGE						
	2017	2017	2017	Analytic Cases Only								
	TOTAL	Analytic	Non-Analytic	M	F	0	I	II	III	IV	UNK	N/A
ALL SITES	394	315	79	137	178	22	69	31	51	78	34	30
BREAST	96	88	8	3	85	17	41	12	10	4	4	0
LUNG: Non-small cell	66	52	14	30	22	0	10	1	9	30	2	0
COLON	28	24	4	14	10	3	1	3	8	7	2	0
NH LYMPHOMA	19	12	7	8	4	0	3	2	2	5	0	1
RECTUM	16	15	1	9	6	1	1	0	5	0	0	0
PANCREAS	14	12	2	5	7	0	0	1	0	10	1	0
ORAL CAVITY/LARYNX	13	7	6	6	1	0	0	1	1	3	2	0
PROSTATE	12	5	7	5	0	0	1	3	0	1	0	0
ESOPHAGUS	12	10	2	8	2	1	1	2	1	2	3	0
LUNG: Small Cell	11	10	1	5	5	0	0	1	3	4	2	0
LEUKEMIA	10	8	2	4	4	0	0	0	0	0	0	8
KIDNEY/RENAL	9	6	3	3	3	0	2	0	1	1	2	1
MULTIPLE MYELOMA	9	5	4	2	3	0	0	0	0	0	0	5
BILIARY	8	8	0	4	4	0	0	1	0	0	4	3
LIVER	7	5	2	4	1	0	0	0	2	2	0	0
FEMALE GYN	7	4	3	0	4	0	1	0	1	1	1	0
MELANOMA	6	5	1	3	2	0	2	1	0	1	1	0
BRAIN (MALIGNANT)	6	6	0	4	2	0	0	0	0	0	0	6
ANUS	6	5	1	2	3	0	0	0	2	5	0	0
THYROID	5	4	1	3	1	0	3	1	0	0	1	0
BLADDER	4	3	1	2	1	0	2	0	1	0	0	0
STOMACH	3	2	1	2	0	0	1	0	0	0	1	0
ALL OTHERS	27	19	8	11	8	0	0	2	6	2	8	6


During 2017, we provided cancer care for 394 new cancer patients. Analytic cases represent patients we provide diagnosis and/or treatment for their cancer. In 2017, we treated 315 analytic patients, representing an overall volume decline of 50 patients compared to 2016. Non-analytic cases represent patients who were diagnosed and treated elsewhere for their cancer and we provided care for their progression or recurrence. There were 23% more females representing our 2017 cases. Lung was divided by non-small cell and small cell cancer types for this analysis.

2017 Cancer Statistics FH DeLand

Annual Case Volumes: 2013-2017

YEAR	Analytic	Non-Analytic	Total
2013	297	18	315
2014	307	27	334
2015	334	63	397
2016	366	111	477
2017	315	79	394

We saw a slight decline in volume in 2017 compared to 2016, nearly matching our volumes in 2015. Analytic cases represent patients we provide diagnosis and/or treatment for their cancer. Non-analytic cases represent patients who were diagnosed and treated elsewhere for their cancer and we provided care for their progression or recurrence.




From 2013-2016, our case volumes have steadily increased. However, we did see a decline in overall volumes of cases in 2017.

2017 Cancer Statistics FH DeLand

Top Cancer Site Trends: 2013-2017


YEAR	BREAST	LUNG	COLON	MELANOMA	THYROID
2013	49	53	28	11	5
2014	78	56	29	11	4
2015	70	54	27	14	4
2016	95	50	40	13	8
2017	88	62	24	5	4



In 2017, our volumes declined in Breast, colon, Melanoma and Thyroid cancers compared to prior years. Lung volume increased during 2017.

2017 Cancer Statistics FH DeLand

Stage at Diagnosis: Top Sites 2017



During 2017 over 65% of our breast cancer patients were diagnosed at very early stage (Stages 0-1). Just over 88% of our breast cancer patients were diagnosed in early stages 0-2. For our lung patients, only 19% were diagnosed as stage 1, however over 57% were diagnosed as stage 4. We have a significant number of colon cancer patient (29.2%) found with metastatic disease at diagnosis.

2016 Cancer Statistics FH DeLand

Cancer Incidence with Comparative Data

2017 Analytic Cases

FH DELAND Incidence % (n=137)	MALE: CANCER TYPE	ACS * Incidence % (n=836,150)
4%	Prostate	21%
11%	Lung	14%
17%	Colon & Retum	8%
1%	Bladder	7%
2%	Melanoma - Skin	6%
2%	Kidney & Renal Pelvis	5%
6%	Non-Hodgkin Lymphoma	5%
4%	Oral Cavity& Pharynx	4%
3%	Leukemia	4%
3%	Liver / Bile Duct	3%

2017 Analytic Cases

FH DELAND Incidence % (n=178)	FEMALE: CANCER TYPE	ACS * Incidence % (n=852,630)
48%	Breast	30%
15%	Lung	12%
9%	Colon & Rectum	8%
1%	Uterine Corpus	7%
1%	Thyroid	5%
2%	Non-Hodgkin Lymphoma	4%
1%	Melanoma - Skin	4%
2%	Kidney & Renal Pelvis	3%
4%	Pancreas	3%
2%	Leukemia	3%

*ACS: American Cancer Society's Cancer Facts and Figures - 2017

For our male population, we have a significantly lower incidence at FH DeLand compared to the nation, due to those patients being diagnosed and treated elsewhere in the community. Our incidence of colon demonstrates a higher incidence in our male population compared to the national data. The incidence for our male population was very similar to those of the comparison data. For our female population, our breast cancer incidence is significantly higher compared to the national data. FH DeLand has a higher incidence of lung and colon and pancreas while we see a lower incidence of Uterine, Thyroid, Lymphoma , Melanoma, Kidney and Leukemia.

Stage at Diagnosis: Comparison with National Database

The following tables outline our stage at diagnosis with comparison to Cancer Programs in Florida of all types and similar types (Community Programs).

BREAST CANCER						
FACILITY/NATIONAL	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	UNKNOWN
	%	%	%	%	%	%
FH DELAND - 2017	19.30%	46.60%	13.60%	11.40%	4.50%	4.50%
FH DELAND - 2016	21.10%	40.00%	26.30%	11.60%	3.20%	0%
FH DELAND - 2015 (n=71)	14%	59%	14%	7%	3%	3%
COC-NATIONAL DATABASE (Community Programs in Florida - 13 hospitals; n=806)	18%	44%	25%	7%	4%	2%
COC-NATIONAL DATABASE (All types of programs in Florida -66 hospitals; n=14070)	23%	40%	23%	8%	4%	3%
COC-NATIONAL DATABASE (All types of programs in Florida; 1303 hospitals; n=230753)	20%	43%	24%	7%	4%	1%

Our stage at diagnosis is very similar to that of other similar programs in Florida. It is noted that our stage 0 has increased from 14% to 19% from 2015- 2017.

COLON CANCER						
FACILITY/NATIONAL	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	UNKNOWN
FH DELAND - 2017	12.5%	4.2%	12.5%	33.3%	29.2%	8.3%
FH DELAND - 2016	5.0%	5.0%	20.0%	30.0%	27.5%	12.5%
FH DELAND - 2015 (n=)	8%	15%	38%	23%	12%	4%
COC-NATIONAL DATABASE (Community Programs in Florida - 13 hospitals; n=382)	3%	15%	24%	28%	21%	9%
COC-NATIONAL DATABASE (All types of programs in Florida - 66 hospitals; n=4513)	6%	19%	24%	27%	19%	5%
COC-NATIONAL DATABASE (All types of programs in Florida; 1303 hospitals; n=70607)	5%	2%	24%	25%	20%	5%

Upon review of our data, we have seen an increase in Stage 0 (intra-mucosal; high-grade dysplasia/in-situ) cases from 2015-2017. During this same time, we have a significant increase in the number of stages 3 and 4 cases compared to comparison data.

LUNG CANCER - NON SMALL CELL					
FACILITY/NATIONAL	STAGE 1	STAGE 2	STAGE 3	STAGE 4	UNKNOWN
FH DELAND - 2017	19.2%	1.9%	17.3%	57.7%	3.8%
FH DELAND - 2016	16.0%	8.0%	28.0%	42.0%	6.0%
FH DELAND - 2015 (n= 61)	25%	2	15%	51%	8%
COC-NATIONAL DATABASE (Community Programs in Florida - 13 hospitals; n=660)	26%	11%	19%	39%	5%
COC-NATIONAL DATABASE (All types of programs in Florida-66 facilities - n= 8178)	31%	10%	19%	38%	2%
COC-NATIONAL DATABASE (All types of programs in US - 1303 Hospitals; n=126131)	39%	9%	19%	41%	2%

We have increasing % of cases of Stages 3 and 4 at Deland compared to 2015. In 2016, 70% of our cases were stages 3 and 4. In 2017, 75% of our cases were stages 3 and 4 compared to 67% of comparison data. Our percent of cases of stage 1 is far less than the nation more similar to data of similar programs in Florida.